目的 探討2021—2024年中國科學院合肥腫瘤醫(yī)院口服小分子靶向抗腫瘤藥物使用情況和發(fā)展趨勢，為該類藥物的合理應用及規(guī)范化管理提供參考依據(jù)。方法 以回顧性分析的方法，收集中國科學院合肥腫瘤醫(yī)院2021年1月1日—2024年12月31日口服小分子靶向抗腫瘤藥物的消耗情況信息，逐年分析藥物品種數(shù)、藥品消耗量、年銷售金額、銷售金額排序、用藥頻度（DDDs）、DDDs排序、限定日費用（DDC）、藥品排序比（B/A）。結果 2021—2024年中國科學院合肥腫瘤醫(yī)院口服小分子靶向抗腫瘤藥物品種為20～23種，年銷售金額呈逐年上升的趨勢，銷售金額居于前3位的品種有安羅替尼、阿帕替尼、阿美替尼、奧希替尼、奧布替尼。2021—2024年總DDDs呈逐年增長的趨勢，DDDs排序居于前3位的品種有阿帕替尼、阿美替尼、吉非替尼、安羅替尼、奧希替尼。2021—2024年總DDC呈現(xiàn)逐年下降的趨勢，其中銷售金額較高的品種中奧希替尼、阿美替尼、阿美替尼的DDC呈現(xiàn)下降趨勢，其中奧希替尼連續(xù)4年B/A均大于1，同步性良好。結論 中國科學院合肥腫瘤醫(yī)院2021—2024年口服小分子靶向抗腫瘤藥物的使用量和銷售金額均呈現(xiàn)逐年增長的趨勢，藥品價格有下降的趨勢，藥品使用消耗情況基本符合國家政策要求趨勢及本院腫瘤臨床治療的實際需求。

Objective To analyze and discuss the use and development trend of oral small molecule targeted anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences from 2021 to 2024, so as to provide a reference for the rational use and standardized management of such drugs. Methods A retrospective analysis was conducted to collect information on the consumption of oral small molecule targeted anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences from January 1, 2021 to December 31, 2024. The number of drug varieties, drug consumption, annual sales amount, sales amount ranking, frequency of use (DDDs), DDDs ranking, daily cost control (DDC), drug ranking ratio (B/A),and other indicators were analyzed year by year. Results From 2021 to 2024, Hefei Cancer Hospital, Chinese Academy of Sciences has 20 — 23 types of oral small molecule targeted anti-tumor drugs, and the annual sales amount has been increasing year by year. The top three varieties in terms of sales amount are anlotinib, apatinib, amitinib, ositinib, and obetinib. From 2021 to 2024, the total DDDs showed an increasing trend year by year, with apatinib, amitinib, gefitinib, anlotinib, and axitinib ranking among the top three DDDs. From 2021 to 2024, the total DDC showed a decreasing trend year by year, among which the DDC of osimertinib, amitinib, and amitinib with higher sales amounts showed a decreasing trend. Among them, osimertinib had a B/A ratio greater than 1 for four consecutive years, indicating good synchronicity. Conclusion The usage and sales amount of oral small molecule targeted anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences from 2021 to 2024 have shown an increasing trend year by year, with a decreasing trend in drug prices. The consumption of drugs is basically in line with the national policy requirements and the actual needs of Hefei Cancer Hospital, Chinese Academy of Sciences's clinical treatment of tumors.

R979.1